A decades-long decline in medical technician training programs and large numbers of looming retirements have labs scrambling to fill their vacancies.
After conducting a head-to-head comparison with competing instruments, clinicians selected the Abbott iStat instrument to monitor blood clotting during surgical interventions.
A Roche executive said he expects essentially all the firm's US troponin customers will convert to the high-sensitivity assay over the next two to three years.
The firm noted that its study showed strong performance data, including high sensitivity and high specificity, in providing results direct from blood.
The QiaStat-Dx system will now be commercially available in the US along with a panel that detects more than 20 respiratory viral and bacterial pathogens.
Oxford Immunotec said that it expects the report to further the trend toward interferon-gamma release assay adoption for healthcare personnel screening.
The Australian firm will use the proceeds for R&D, expansion in China, and to fund the development of polygenic risk tests with TGen in the US.
The company reported revenues of $222.5 million, down from $254.9 million in Q1 2018, and below the consensus Wall Street estimate of $241.3 million.